KEYNOTE-826 trial met its dual primary endpoints
Survival benefit with first-line pembrolizumab plus chemotherapy in persistent, recurrent or metastatic cervical cancer
Novel immunotherapy-containing strategies look promising in microsatellite stable mCRC
Immune chemo-sensitisation results show potential for this approach in the treatment of advanced CRC, but greater understanding of response characteristics is required in future clinical trials
The role of T-VEC in the treatment of advanced melanoma: just a matter of combinations?
The oncolytic herpes virotherapy does not show survival benefit in combination with pembrolizumab, but encouraging early data are reported with intratumoural injection of myeloid dendritic cells
Novel liquid biomarkers show promise in predicting clinical outcomes with immunotherapy
Although encouraging results are presented, standardisation of methodology and large-scale clinical trials are needed before potential candidates can be used in routine clinical practice
Early-stage HER2+ breast cancer may benefit from de-escalated treatment, but biomarkers are still required
Findings from three studies highlight that selecting patients for de-escalated treatment is still challenging
Positive preliminary data with the T-cell receptor fusion construct, gavocabtagene autoleucel
Manageable toxicity profile and signs of clinical benefit seen with gavocabtagene autoleucel in treatment-refractory mesothelin-expressing solid tumours
Novel approaches to improve immunotherapy and more news on synthetic lethality
The ESMO Congress 2021 has started today with three sessions on developmental therapeutics, including immunotherapy. The overarching theme in these sessions is the improvement of checkpoint inhibitor-based immunotherapy and a new flavour of synthetic lethality in molecularly pre-defined solid tumours.